1-20 of 654
Sort by
News

Clonal Hematopoiesis Associated With Cytopenias After CAR-T Therapy for MM

Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, Clonal Hematopoiesis Associated With Cytopenias After CAR-T Therapy for MM
News

Study of LBCL Confirms Prognostic Value of ctDNA in Second-Line Liso-Cel Versus Standard of Care

Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, Study of LBCL Confirms Prognostic Value of ctDNA in Second-Line Liso-Cel Versus Standard of Care
News

Teclistamab Safe for Treating Patients with R/R MM with Renal Impairment

Thomas R. Collins
Published: 2025
Abstract
April 2025
View News titled, Teclistamab Safe for Treating Patients with R/R MM with Renal Impairment
News

Extramedullary Disease Helps Predict Immune Effector Cell Toxicities After CAR-T in MM

Thomas R. Collins
Published: 2025
Abstract
April 2025
View News titled, Extramedullary Disease Helps Predict Immune Effector Cell Toxicities After CAR-T in MM
News

Clonal Hematopoiesis May Prolong Cytopenias After CAR-T Therapy for MM

Katie Robinson
Published: 2025
Abstract
February 2025
View News titled, Clonal Hematopoiesis May Prolong Cytopenias After CAR-T Therapy for MM
News

CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study

Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, CAR-T Shows Acceptable Efficacy, Safety in Phase II R/R T-ALL/LBL Study
News

Physical Function Can Help Gauge ICANS Risk, Study Finds

Thomas R. Collins
Published: 2025
Abstract
April 2025
View News titled, Physical Function Can Help Gauge ICANS Risk, Study Finds
News

Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM

Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Non-Viral, Allogeneic BCMA-Directed CAR-T Therapy Eliminates Bridging in R/R MM
News

Multimodal Machine Learning Boosts CAR-T Outcome Prediction in LBCL

Thomas R. Collins
Published: 2025
Abstract
April 2025
View News titled, Multimodal Machine Learning Boosts CAR-T Outcome Prediction in LBCL
News

Cilta-Cel Treatment in Lenalidomide-Refractory MM Results in High Rates of MRD Negativity

Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, Cilta-Cel Treatment in Lenalidomide-Refractory MM Results in High Rates of MRD Negativity
News

Study Highlights Characteristics of Post-CAR-T Treatment–Related Myeloid Neoplasms

Katie Robinson
Published: 2025
Abstract
April 2025
View News titled, Study Highlights Characteristics of Post-CAR-T Treatment–Related Myeloid Neoplasms
News

IL-15 Agonist Boosts Response in Phase II LBCL CAR-T Trial

Thomas R. Collins
Published: 2025
Abstract
February 2025
View News titled, IL-15 Agonist Boosts Response in Phase II LBCL CAR-T Trial
News

Predicting Response to Obe-Cel in Patients With R/R B-ALL

Lara C. Pullen, PhD
Published: 2025
Abstract
April 2025
View News titled, Predicting Response to Obe-Cel in Patients With R/R B-ALL
News

Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups

Katie Robinson
Published: 2024
Abstract
January 2025
View News titled, Daratumumab Plus Lenalidomide Shows MRD, PFS Benefit in Newly Diagnosed MM After AHCT in Clinically Relevant Subgroups
News

Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab

Lara C. Pullen, PhD
Published: 2024
Abstract
January 2025
View News titled, Patients in R/R Marginal Zone Lymphoma Cohort of ELM-2 Show Superior Outcomes With Odronextamab
News

Bispecific T-Cell Engager Results in CR, Clears MRD in Patients with R/R Follicular Lymphoma

Anna Azvolinsky, PhD
Published: 2024
Abstract
January 2025
View News titled, Bispecific T-Cell Engager Results in CR, Clears MRD in Patients with R/R Follicular Lymphoma
News

Initial Results Confirm Safety of Lower-Dose Teclistamab as Maintenance in NDMM

Khylia Marshall
Published: 2024
Abstract
January 2025
View News titled, Initial Results Confirm Safety of Lower-Dose Teclistamab as Maintenance in NDMM
News

Teclistamab-Based Induction Regimens Achieve MRD Negativity in Patients With Transplant-Eligible NDMM

Katie Robinson
Published: 2024
Abstract
January 2025
View News titled, Teclistamab-Based Induction Regimens Achieve MRD Negativity in Patients With Transplant-Eligible NDMM
News

Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma

Lara C. Pullen, PhD
Published: 2024
Abstract
January 2025
View News titled, Daratumumab Shows Better Outcomes Than Active Monitoring for Smoldering Multiple Myeloma
News

Quadruple Combination with Brentuximab Vedotin, Nivolumab Continues to Show Strong Efficacy in Early-Stage cHL

Anna Azvolinsky, PhD
Published: 2024
Abstract
January 2025
View News titled, Quadruple Combination with Brentuximab Vedotin, Nivolumab Continues to Show Strong Efficacy in Early-Stage cHL